InO with or without donor cells for relapsed B-ALL after stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a drug called InO (inotuzumab ozogamicin) with or without donor white blood cells (DLI) for people whose B-ALL or LBL has returned after a stem cell transplant. The goal is to see if this treatment helps control the cancer with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 65 years old.
- You have B-ALL or LBL that is CD22-positive and it came back after a stem cell transplant.
- You are generally able to care for yourself (ECOG score 0-3, Karnofsky score at least 70).
- You do not have active or severe graft-versus-host disease (GvHD) or a history of veno-occlusive disease (VOD).
- Your kidneys, liver, and heart are working well enough (as checked by tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This trial tests whether a drug called inotuzumab can help prevent leukemia from returning after you have had a stem cell transplant (also called a bone marrow transplant). The study is for adults with a type of leukemia that is considered high-risk, and the drug is given after transplant to try to keep the cancer in remission.
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
Hear when a new Leukemia, Lymphocytic, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.